Published: 19. August, 2021
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1…
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2021. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor, ‘Filings & Reports’. The company is on track with planned activities, has completed recruitment for the bioavailability trial 0204 and is ready to initiate recruitment of trial 0206 – a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures.
“The second quarter of 2021 has focused much on clinical activities, with coordinating and executing three (3) clinical trials in parallel – in particular preparing for the pivotal trial 0205 with more than 220 patients has been a major effort, more will continue in Q3 and Q4. The Company was awarded IPO of the year by Affärsvälden, which was another recognition of our hard work and we are proud to have initiated early formulation activities for our second product candidate CT002 – the outlook is really positive for the Company and it looks like 2021 will be a promising year” says Jes Trygved, CEO